Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
To assess safety and tolerability of patients converting from approved Relapsing Multiple
Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Multiple Sclerosis
Enrollment Eligibility
Key Inclusion Criteria:
1. Signed informed consent.
2. Male or female aged 18 to 65 years (inclusive).
3. Patients with advancing RMS as defined by the principal investigator.
4. Prior history of relapsing MS (RMS), with or without progressive features, according
to the 2010 Revised McDonald or Lublin criteria (Lublin et al, 2013).
5. EDSS score of >/= 2.0 to 6.5 (inclusive).
6. Having been continuously treated with RMS Disease Modifying Therapies.
Key Exclusion criteria:
1. Pregnant or nursing (lactating) women.
2. Patients with any medically unstable condition as determined by the investigator.
3. Certain cardiac risk factors defined in the protocol
4. History of hypersensitivity to the study drug or to drugs of similar chemical classes.
Other protocol-defined inclusion/exclusion criteria may apply.